CRSP - CRISPR Therapeutics - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

3.455B

Cash

1.883B

Avg Qtr Burn

-87.93M

Short % of Float

15.96%

Insider Ownership

1.49%

Institutional Own.

67.98%

Qtr Updated

03/31/23

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Exagamglogene autotemcel (CTX001) (autologous CRISPR/Cas9 gene-edited hematopoietic stem cell therapy) Details Beta thalessemia	BLA Acceptance for review	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Exagamglogene autotemcel (CTX001) (autologous CRISPR/Cas9 gene-edited hematopoietic stem cell therapy) Details Sickle cell disease	BLA Acceptance for review	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CTX110 (CD19) Details CD19+ malignancies, Blood cancer, Cancer, B-cell malignancies	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Exagamglogene autotemcel (CTX001) (autologous CRISPR/Cas9 gene-edited hematopoietic stem cell therapy) Details Sickle cell disease	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Exagamglogene autotemcel (CTX001) (autologous CRISPR/Cas9 gene-edited hematopoietic stem cell therapy) Details Beta thalessemia	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
VCTX210 Details Type 1 diabetes	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CTX130 (CD70) Details Solid tumor/s, Blood cancer, Cancer	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CTX120 (BCMA) Details Multiple myeloma, Blood cancer, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.